Miricorilant

DRUG7 trials

Sponsors

Corcept Therapeutics, The Scripps Research Institute

Conditions

Alcohol Use DisorderAntipsychotic Induced Weight GainAntipsychotic-induced Weight Gain (AIWG)Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 1

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

CompletedNCT05553470

Corcept TherapeuticsNon-alcoholic Steatohepatitis (NASH)

Start: 2022-03-03End: 2024-09-13Updated: 2025-03-30

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

CompletedNCT05712265

Corcept TherapeuticsAntipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)

Start: 2023-01-24End: 2023-02-23Updated: 2023-03-22

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Active, not recruitingNCT06947304

Corcept TherapeuticsMetabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD) +1

Start: 2025-08-22End: 2026-09-01Updated: 2026-07-30

Evaluating the Pharmacokinetics and Safety of Miricorilant

RecruitingNCT07553663

Corcept TherapeuticsMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD) +1

Start: 2026-04-30End: 2026-10-30Target: 15Updated: 2026-05-26

Phase 2

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

CompletedNCT03818256

Corcept TherapeuticsAntipsychotic-induced Weight Gain (AIWG)

Start: 2019-12-04End: 2022-07-06Updated: 2024-09-19

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

TerminatedNCT03823703

Corcept TherapeuticsNonalcoholic Steatohepatitis (NASH)

Start: 2020-11-04End: 2021-04-05Updated: 2022-08-31

Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo

CompletedNCT04466215

The Scripps Research InstituteAlcohol Use Disorder

Start: 2021-04-15End: 2022-06-07Updated: 2023-02-03